Paul J. Hergenrother, PhD, is a Professor of Chemistry, and Affiliate in Biochemistry, and the Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry. Professor Hergenrother is the co-founder and Chief Scientific Officer of Vanquish Oncology, and an anticancer compound discovered by the Hergenrother lab is now being taken by cancer patients at the University of Illinois Cancer Center and at Johns Hopkins as part of a Phase 1 clinical trial. At the University of Illinois Professor Hergenrother is the Leader of the IGB Theme “Anticancer Discovery from Pets to People”, and is the Director of the NIH Chemistry-Biology Interface Training Grant. The Hergenrother laboratory seeks to use small molecules to identify and validate novel targets for the treatment of intractable cancers.
Areas of Research
Brain Cancer, Breast Cancer, Chemistry - Drug Discovery